Literature DB >> 2459119

Monoclonal antibodies to three phospholipase C isozymes from bovine brain.

P G Suh1, S H Ryu, W C Choi, K Y Lee, S G Rhee.   

Abstract

Murine hybridoma cell lines secreting antibodies against the three bovine isozymes of phosphoinositide-specific phospholipase C (PLC) were established: 6, 23, and 12 lines were obtained for PLC-I (150 kDa), PLC-II (145 kDa), and PLC-III (85 kDa), respectively. The antibodies were purified from ascites fluid, and their properties were studied in detail. All the antibodies cross-reacted with their corresponding PLC enzymes, but not with the other two isozymes, suggesting that the three enzymes contain very different antigenic determinants. The six antibodies elicited by bovine PLC-I also cross-reacted with human and rat enzyme, whereas three each from anti-PLC-II antibodies and anti-PLC-III antibodies did not react with the enzymes from different species. Each antibody exerts different effects on the phosphatidylinositol-hydrolyzing activity of PLC. The most inhibitory antibody for either isozyme PLC-I or PLC-II exhibits 80% inhibition, whereas no more than 20% inhibition was observed for the anti-PLC-III antibodies. Purified PLC-I frequently contains catalytically active 140- and 100-kDa forms and an inactive 41-kDa protein in addition to the intact 150-kDa form, probably due to its high sensitivity to an unidentified endogenous protease. The five anti-PLC-I antibodies which bind to the denatured 150-kDa polypeptide also recognized the 140-kDa form, whereas only three cross-reacted with the 100-kDa form, and the remaining two bound to the 41-kDa protein. Competitive binding studies with intact PLC enzymes and Western blot experiments with proteolytic digests revealed that the 6 anti-PLC-I, 23 anti-PLC-II, and 12 anti-PLC-III antibodies bind at least five, six, and seven different epitopes on PLC-I, PLC-II, and PLC-III, respectively. The fact that these monoclonal antibodies bind to different epitopes on the same enzyme allowed one to develop a highly specific and sensitive tandem radioimmunoassay for quantitating PLC-I, PLC-II, and PLC-III. The principle of the assay is that binding of an 125I-labeled antibody to the antigen immobilized by another antibody at a distinctive binding site is proportional to the amount of antigen present. By using this method, PLC-I, PLC-II, and PLC-III could be measured quantitatively in the presence of other proteins, detergents, lipids, polyanions, and metal ions, all of which greatly affect the activity of PLC enzymes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459119

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Phospholipase Cdelta1 is required for skin stem cell lineage commitment.

Authors:  Yoshikazu Nakamura; Kiyoko Fukami; Haiyan Yu; Kei Takenaka; Yuki Kataoka; Yuji Shirakata; Shin-Ichi Nishikawa; Koji Hashimoto; Nobuaki Yoshida; Tadaomi Takenawa
Journal:  EMBO J       Date:  2003-06-16       Impact factor: 11.598

2.  Regulation of CD3-induced phospholipase C-gamma 1 (PLC gamma 1) tyrosine phosphorylation by CD4 and CD45 receptors.

Authors:  S B Kanner; J P Deans; J A Ledbetter
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

3.  Platelet-derived growth factor (PDGF)-dependent association of phospholipase C-gamma with the PDGF receptor signaling complex.

Authors:  D K Morrison; D R Kaplan; S G Rhee; L T Williams
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

4.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency.

Authors:  F Fazioli; U H Kim; S G Rhee; C J Molloy; O Segatto; P P Di Fiore
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C.

Authors:  Q C Vega; C Cochet; O Filhol; C P Chang; S G Rhee; G N Gill
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

6.  Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-gamma 1 by a kinase activity associated with the product of the trk protooncogene.

Authors:  M L Vetter; D Martin-Zanca; L F Parada; J M Bishop; D R Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

7.  Transmembrane signalling at the epidermal growth factor receptor. Positive regulation by the C-terminal phosphotyrosine residues.

Authors:  M Magni; A Pandiella; K Helin; J Meldolesi; L Beguinot
Journal:  Biochem J       Date:  1991-07-15       Impact factor: 3.857

8.  Tyrosine mutations within the alpha platelet-derived growth factor receptor kinase insert domain abrogate receptor-associated phosphatidylinositol-3 kinase activity without affecting mitogenic or chemotactic signal transduction.

Authors:  J C Yu; M A Heidaran; J H Pierce; J S Gutkind; D Lombardi; M Ruggiero; S A Aaronson
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

9.  Platelet-derived growth factor induces rapid and sustained tyrosine phosphorylation of phospholipase C-gamma in quiescent BALB/c 3T3 cells.

Authors:  M I Wahl; N E Olashaw; S Nishibe; S G Rhee; W J Pledger; G Carpenter
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

10.  SNT, a differentiation-specific target of neurotrophic factor-induced tyrosine kinase activity in neurons and PC12 cells.

Authors:  S J Rabin; V Cleghon; D R Kaplan
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.